Resources

Resource thumbail

The people’s prescription: Re-imagining health innovation to deliver public value

October 2018

Driven by profit rather than public health, the pharmaceutical sector is incentivised to set high prices and deliver short-term returns to shareholders, rather than focus on riskier, longer-term research which leads to critically needed therapeutic advances. The high prices of medicines are causing severe patient access problems worldwide, with damaging consequences for human health and wellbeing. These are symptoms of an innovation model that is broken. This report maps the fault lines of this system and sets out principles for a new one.

Resource thumbail

Pills and Profits: How drug companies make a killing out of public research

October 2017

UK taxpayers and patients worldwide are being denied the medicines they need, despite the public sector playing a pivotal role in the discovery of new medicines. The UK government is the second largest funder country, after the US, for research and development (R&D) in diseases that predominantly affect poor countries. Across all areas of health R&D, the UK government spent £2.3 billion on health R&D in 2015 alone.